Home » Newsletters » BioWorld Science

BioWorld Science

May 25, 2012

View Archived Issues

Novel cytochrome P450 inhibitors patented by German university

Research in Korea yields new HIF1-alpha inhibitors

Ardelyx describes novel phosphate transport inhibitors

Pfizer describes novel antiandrogen for castration-resistant prostate cancer

High-risk prostate carcinoma-related death linked to miR-221 expression

Bionomics commences phase I/II trial of vasculature-disrupting agent in ovarian cancer

Genmab receives Arzerra milestone payment

In vivo results presented for new antibody-drug conjugate

Novel treatments for Parkinson's disease prepared at Merck & Co.

Scientists at Nektar Therapeutics present new polymer-GLP-1 conjugates

Morphotek produces novel monoclonal antibodies for cancer

Merck & Co. describes novel protein kinase inhibitors

Rigel presents preclinical data for new antiasthma drug candidate

Anti-IL10 receptor monoclonal antibody enhances BCG antitumor responses

XenoPort submits IND for potential multiple sclerosis treatment

Second cohort opens enrollment in ATOMIC-AHF trial

Lucigen receives NIH grant for RNA-based diagnostic

Kancera's ROR inhibitors show activity against fludarabine-resistant CLL

Oryzon set to begin preclinical development of hematological cancer drug

Chugai files for approval in Japan of pertuzumab

PharmaGap conditionally approves offer for GAP-107B8 license

IMI launches public-private research program to combat antibiotic resistance

Shionogi obtains additional approvals for carbapenem-type antibiotic in Japan

FDA advisory committee votes on Pfizer's data package for TTR stabilizer

RetroSense Therapeutics obtains guidance for lead biologic for eye diseases

AstraZeneca obtains approval for Inderal for new indication in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld Science
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...